US equities |
MU $1,079.13 ▲+1.32% NVDA $231.64 ▲+1.43% SNDK $1,777.49 ▲+2.16% INTC $120.94 ▲+0.59% TSLA $357.18 ▲+0.67% GOOGL $338.86 ▼-1.52% SPCX $150.20 ▼-0.44% AMD $617.51 ▲+0.94%
FinancialContent Watchlist

MaxCyte, Inc. - Common Stock (NQ:MXCT)

1.105 -0.015 (-1.34%)
Delayed Quote Updated: 2:34 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte (MXCT) Q2 2026 Earnings Call Transcript ↗
Revenue declined 15% year-over-year, but net losses narrowed significantly. 
Via The Motley Fool
Topics Earnings
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback ↗
Via Chartmill
MaxCyte Inc (NASDAQ:MXCT) Reports Q4 2025 Revenue Miss and Cautious 2026 Outlook ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Q2 Earnings Call Highlights ↗
MaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year... 
Via MarketBeat
Topics Earnings
News headline image
MaxCyte Reports Second Quarter 2026 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
From MaxCyte, Inc
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
MaxCyte Q1 Earnings Call Highlights ↗
MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core... 
Via MarketBeat
Topics Earnings
News headline image
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript ↗
MaxCyte (MXCT) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Planned CFO Transition in 2026
Company initiates search for successor 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
Insights into MaxCyte's Upcoming Earnings ↗
 
Via Benzinga
News headline image
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapies 
From MaxCyte, Inc
Via GlobeNewswire
News headline image
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
From MaxCyte, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >